NO20061744L - Terapeutisk behandling - Google Patents

Terapeutisk behandling

Info

Publication number
NO20061744L
NO20061744L NO20061744A NO20061744A NO20061744L NO 20061744 L NO20061744 L NO 20061744L NO 20061744 A NO20061744 A NO 20061744A NO 20061744 A NO20061744 A NO 20061744A NO 20061744 L NO20061744 L NO 20061744L
Authority
NO
Norway
Prior art keywords
therapeutic treatment
prevention
treatment
candesartan
rosuvastatin
Prior art date
Application number
NO20061744A
Other languages
English (en)
Other versions
NO335813B1 (no
Inventor
Jay Lal Mehta
Original Assignee
Astrazeneca Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Uk Ltd filed Critical Astrazeneca Uk Ltd
Publication of NO20061744L publication Critical patent/NO20061744L/no
Publication of NO335813B1 publication Critical patent/NO335813B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Materials For Medical Uses (AREA)

Abstract

Det beskrives en kombinasjon som omfatter kandesartan og rosuvastatin for forebyggelse eller behandling av aterosklerose og for forebyggelse av kardiovaskulære hendelser.
NO20061744A 2003-09-26 2006-04-20 Kombinasjon omfattende kandesartan eller et farmasøytisk akseptabelt salt derav og rosuvastatin eller et farmasøytisk akseptabelt salt derav for forebygging eller behandling av sykdom NO335813B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0322552.1A GB0322552D0 (en) 2003-09-26 2003-09-26 Therapeutic treatment
PCT/GB2004/004120 WO2005030215A2 (en) 2003-09-26 2004-09-22 Therapeutic treatment

Publications (2)

Publication Number Publication Date
NO20061744L true NO20061744L (no) 2006-06-22
NO335813B1 NO335813B1 (no) 2015-02-23

Family

ID=29286881

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20061744A NO335813B1 (no) 2003-09-26 2006-04-20 Kombinasjon omfattende kandesartan eller et farmasøytisk akseptabelt salt derav og rosuvastatin eller et farmasøytisk akseptabelt salt derav for forebygging eller behandling av sykdom

Country Status (28)

Country Link
US (2) US7932263B2 (no)
EP (1) EP1673091B1 (no)
JP (1) JP4841433B2 (no)
KR (1) KR101129767B1 (no)
CN (1) CN100515421C (no)
AT (1) ATE451103T1 (no)
AU (1) AU2004275567B2 (no)
BR (1) BRPI0414724A (no)
CA (1) CA2540102C (no)
CY (1) CY1109814T1 (no)
DE (1) DE602004024555D1 (no)
DK (1) DK1673091T3 (no)
ES (1) ES2336450T3 (no)
GB (1) GB0322552D0 (no)
HR (1) HRP20100080T1 (no)
IL (1) IL174536A (no)
IS (1) IS2729B (no)
MX (1) MXPA06003353A (no)
NO (1) NO335813B1 (no)
NZ (1) NZ546162A (no)
PL (1) PL1673091T3 (no)
PT (1) PT1673091E (no)
RU (1) RU2358737C2 (no)
SG (1) SG145773A1 (no)
SI (1) SI1673091T1 (no)
UA (1) UA90249C2 (no)
WO (1) WO2005030215A2 (no)
ZA (1) ZA200602433B (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0001662D0 (en) * 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
GB0003305D0 (en) 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
GB0218781D0 (en) 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
WO2007051007A2 (en) * 2005-10-28 2007-05-03 Novartis Ag Combination of antihypertensives with cholesterol-lowering agent
BR112012006939A2 (pt) * 2009-09-29 2015-09-08 Butamax Tm Advanced Biofuels célula hospedeira de produção de levedura recombinante e método para a produção de um produto selecionado do grupo que consiste em 2,3-butanodiol, isobutanol, 2-butanol, 1-butanol, 2-butanona, valina, leucina, ácido lático, ácido málico, álcool, isoampilico e isoprenoides
US20120239131A1 (en) * 2011-03-15 2012-09-20 Medtronic Vascular, Inc. Methods and apparatus for treatment of aneurysmal tissue
WO2013083286A1 (en) * 2011-12-09 2013-06-13 Farmicom Pharmaceutical Company D.O.O. TREATMENT OF ARTERIAL WALL BY COMBINATION OF RAAS INHIBITOR AND HMG-CoA REDUCTASE INHIBITOR
CN103479627A (zh) * 2013-05-16 2014-01-01 武汉光谷百桥国际生物科技有限公司 一种血管紧张素ii的i型受体拮抗剂在促进毛发生长方面的应用
KR101771766B1 (ko) 2013-12-30 2017-08-28 알보젠코리아 주식회사 안지오텐신-Ⅱ 수용체 차단제 및 HMG-CoA 환원효소 저해제를 포함하는 약제학적 복합제제
UA122847C2 (uk) * 2016-11-15 2021-01-06 Елджі Кем, Лтд. Лікувальний комплекс для лікування діабету другого типу та діабетичної дисліпідемії

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5196444A (en) * 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
US6004989A (en) * 1990-04-27 1999-12-21 Takeda Chemical Industries, Ltd. Benzimidazole derivatives, their production and use
US5703110A (en) * 1990-04-27 1997-12-30 Takeda Chemical Industries, Ltd. Benzimidazole derivatives, their production and use
US5298497A (en) * 1990-05-15 1994-03-29 E. R. Squibb & Sons, Inc. Method for preventing onset of hypertension employing a cholesterol lowering drug
CA2040865C (en) 1990-05-15 2002-07-23 James L. Bergey Method for preventing, stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
WO1993008823A1 (en) 1991-11-06 1993-05-13 Tanabe Seiyaku Co., Ltd. Guanidinyl and related cell adhesion modulation compounds
CA2125251C (en) 1993-06-07 2005-04-26 Yoshiyuki Inada A pharmaceutical composition for angiotensin ii-mediated diseases
US5721263A (en) * 1993-06-07 1998-02-24 Takeda Chemical Industries, Ltd. Pharmaceutical composition for angiotensin II-mediated diseases
CA2186606A1 (en) * 1994-03-29 1995-10-05 Edward B. Nelson Treatment of atherosclerosis with angiotensin ii receptor blocking imidazoles
FR2741620B1 (fr) 1995-11-28 1997-12-26 Oreal Procede de preparation de composes a groupement beta-hydroxy -delta-lactone analogues de la (+) compactine et de la (+) mevinoline
PL189066B1 (pl) 1996-04-05 2005-06-30 Takeda Pharmaceutical Kompozycja farmaceutyczna do zapobiegania lub zwalczania chorób związanych z angiotensyną II oraz stosowanie związków do wytwarzania leku do zapobiegania lub zwalczania chorób związanych z angiotensyną II
DE69734405T2 (de) * 1996-07-15 2006-08-03 Sankyo Co., Ltd. Verwendung von CS-866 (Olmersartan) zur Herstellung eines Medikaments für die Behandlung von Arteriosklerose
JPH1081633A (ja) 1996-07-16 1998-03-31 Sankyo Co Ltd 医薬組成物
GT199800126A (es) 1997-08-29 2000-01-29 Terapia de combinacion.
HN1998000124A (es) 1997-08-29 1999-02-09 Pfizer Prod Inc Terapia de combinacion
GB9900339D0 (en) 1999-01-09 1999-02-24 Zeneca Ltd Chemical compounds
AR022462A1 (es) 1999-02-06 2002-09-04 Astrazeneca Uk Ltd Uso de un agente que disminuye el colesterol
GB0000710D0 (en) 1999-02-06 2000-03-08 Zeneca Ltd Drug combination
GB0001662D0 (en) * 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
GB9903472D0 (en) 1999-02-17 1999-04-07 Zeneca Ltd Chemical process
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
TR200102944T2 (tr) 1999-04-13 2002-08-21 Basf Aktiengesellschaft İntegrin reseptör ligandları
PL353199A1 (en) 1999-08-30 2003-11-03 Aventis Pharma Deutschland Gmbh Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events
AU782386C (en) 1999-08-31 2006-08-10 Brigham And Women's Hospital Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
GB0001621D0 (en) 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
GB0003305D0 (en) 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
WO2001072706A1 (en) 2000-03-28 2001-10-04 Biocon India Limited Synthesis of [r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)
AR030414A1 (es) 2000-04-03 2003-08-20 Astrazeneca Ab Combinacion farmaceutica que comprende un beta bloqueante y un inhibidor de hmg-coa reductasa , formulacion farmaceutica, equipo transportable de partes , uso de esta combinacion y de esta formulacion para preparar medicamentos
GB2361185A (en) 2000-04-10 2001-10-17 Nicholas J Wald Pharmaceutical formulation for the prevention of cardiovascular disease
RU2298418C2 (ru) * 2000-04-12 2007-05-10 Новартис Аг Комбинация по меньшей мере двух соединений, выбранных из групп антагонистов at1-рецептора или ингибиторов асе (ангиотензинпревращающий фермент), или ингибиторов hmg-coa-редуктазы (бета-гидрокси-бета-метилглутарил-кофермент-а-редуктаза)
US6620821B2 (en) * 2000-06-15 2003-09-16 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
WO2002017913A1 (en) * 2000-08-30 2002-03-07 Sankyo Company, Limited Medicinal compositions for preventing or treating heart failure
JP2002145770A (ja) * 2000-08-30 2002-05-22 Sankyo Co Ltd 心不全の予防又は治療のための医薬組成物
GB0028429D0 (en) 2000-11-22 2001-01-10 Astrazeneca Ab Therapy
PT1385548E (pt) * 2001-01-26 2007-08-24 Schering Corp Combinações de um inibidor ou de inibidores de absorção de esteróis com agente (s) para o tratamento de doenças vasculares
AR035533A1 (es) * 2001-01-26 2004-06-02 Schering Corp Uso de por lo menos un inhibidor de la absorcion de los esteroles o sus sales, solvatos, prodrogas farmaceuticamente aceptables o mezclas de los mismos para la preparacion de un medicamento para el tratamiento de la sitosterolemia, composiciones farmaceuticas, el uso de dichas composiciones para la
WO2002095402A2 (en) * 2001-04-18 2002-11-28 Mcgill University Individualization of therapy with hyperlipidemia agents
SE0103509D0 (sv) 2001-10-19 2001-10-19 Astrazeneca Ab Rosuvastatin in pre demented states
EA008596B1 (ru) 2003-04-29 2007-06-29 Пфайзер Инк. 5,7-ДИАМИНОПИРАЗОЛО[4,3-d]ПИРИМИДИНЫ, ПОЛЕЗНЫЕ ПРИ ЛЕЧЕНИИ ГИПЕРТЕНЗИИ
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
UY28501A1 (es) 2003-09-10 2005-04-29 Astrazeneca Uk Ltd Compuestos químicos
GB0321827D0 (en) 2003-09-18 2003-10-15 Astrazeneca Uk Ltd Chemical compounds
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
JP2005126338A (ja) 2003-10-21 2005-05-19 Boehringer Ingelheim Pharma Gmbh & Co Kg 心不全治療剤
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
US20060078615A1 (en) 2004-10-12 2006-04-13 Boehringer Ingelheim International Gmbh Bilayer tablet of telmisartan and simvastatin

Also Published As

Publication number Publication date
AU2004275567B2 (en) 2008-01-10
IS8421A (is) 2006-04-21
DE602004024555D1 (de) 2010-01-21
DK1673091T3 (da) 2010-03-22
HK1090553A1 (en) 2006-12-29
JP4841433B2 (ja) 2011-12-21
IL174536A (en) 2010-12-30
US7932263B2 (en) 2011-04-26
PT1673091E (pt) 2010-02-15
AU2004275567A1 (en) 2005-04-07
ZA200602433B (en) 2007-06-27
IS2729B (is) 2011-04-15
SG145773A1 (en) 2008-09-29
US20110046119A1 (en) 2011-02-24
IL174536A0 (en) 2008-04-13
CA2540102A1 (en) 2005-04-07
RU2358737C2 (ru) 2009-06-20
ES2336450T3 (es) 2010-04-13
CY1109814T1 (el) 2014-09-10
EP1673091B1 (en) 2009-12-09
RU2006113366A (ru) 2007-11-10
KR101129767B1 (ko) 2012-03-26
EP1673091A2 (en) 2006-06-28
MXPA06003353A (es) 2006-06-08
BRPI0414724A (pt) 2006-11-21
SI1673091T1 (sl) 2010-03-31
ATE451103T1 (de) 2009-12-15
WO2005030215A3 (en) 2005-06-02
CN100515421C (zh) 2009-07-22
CA2540102C (en) 2012-07-24
JP2007506720A (ja) 2007-03-22
NO335813B1 (no) 2015-02-23
UA90249C2 (uk) 2010-04-26
PL1673091T3 (pl) 2010-04-30
CN1886136A (zh) 2006-12-27
GB0322552D0 (en) 2003-10-29
WO2005030215A2 (en) 2005-04-07
KR20060108623A (ko) 2006-10-18
HRP20100080T1 (hr) 2010-04-30
NZ546162A (en) 2008-11-28
US20070275989A1 (en) 2007-11-29

Similar Documents

Publication Publication Date Title
CY1109814T1 (el) Ενας συνδυασμος που περιεχει candesartan και rosuvastatin για τη θεραπευτικη αντιμετωπιση της αρτηριοσκληρυνσης
NO20054369D0 (no) Anvendelse av en IBAT-inhibitor for behandling og profylakse av forstoppelse
CY1110385T1 (el) Χρηση αναστολεων της il-18 για τη θεραπεια και/ή προληψη της αθηροσκληρωσης
AU2004208615B2 (en) Medicine for prevention of and treatment for arteriosclerosis and hypertension
DE60124684D1 (de) Sulfonamido-substituierte verbrückte bicycloalkylderivative
DK1487541T3 (da) Anvendelse af IL-18-inhibitorer til behandling og/eller forebyggelse af perifere vaskulære sygdomme
EA200300953A1 (ru) Терапевтические комбинации для применения при сердечно-сосудистых и воспалительных заболеваниях
MY137250A (en) Method of treatment of transplant rejection
NO20051521D0 (no) Anvendelse av kombinasjonen av ciclesonid og antihistaminer for behandlingen av allergisk rhinitt
ATE469886T1 (de) 17beta-hydroxysteroid dehydrogenase typ-3 hemmer zur behandlung von androgen abhängigen erkrankungen
EE200300328A (et) IL-18 inhibiitorite kasutamine südamehaiguse raviks ja/või ennetamiseks
AR043327A1 (es) Uso de inhibidores de quinurenina 3- hidroxilasa para el tratamiento de la diabetes
DK1530462T3 (da) 1-phenyl-2-dimethylaminomethylcyclohexanforbindelser til behandling af depressionssymtomer. smerte og inkontinens
TW200503707A (en) Application of intestinal biliary acid reuptake inhibitors for the prevention and threatment of alzheimer's disease
NO20054700L (no) Anvendelse av et fibrat og orlistat for behandling av fedme
DE50301665D1 (de) Torblatthandgriff sowie Verwendung desselben
NO20054020D0 (no) Medisin for forhindring og behandling av arterosklerose og hypertensjon
NO20053247L (no) Anvendelse av levocetirizin ved behandling av vedvarende allergisk rhinitt.
DE60111571D1 (de) Verwendung von anethol-dithiolethion zur vorbeugung und behandlung der sehnentoxizität
ATE552888T1 (de) Elastasehemmer bei leukämie
NO20062138L (no) Anvendelse av ifenprodil i behandling av smerte
UA6012U (en) Remedy for topical treatment of infected skin wounds
DK1299102T3 (da) Anvendelse af riluzol eller salte deraf til forebyggelse og behandling af adrenoleukodystrofi

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees